{"analyses":[{"ciLowerLimit":"0.277","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.391","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7103","paramType":"Odds Ratio (OR)","paramValue":"0.813","statisticalComment":"P-value from Cochran-Mantel-Haenszel test stratified by baseline age group","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.1","upperLimit":"68.5","value":"45.0"},{"groupId":"OG001","lowerLimit":"25.6","upperLimit":"56.7","value":"40.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Rescue medication is any medication (other than excluded medications) that is intended to increase platelet counts or prevent bleeding.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received weekly subcutaneous placebo for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\\^9/L.","id":"OG001","title":"Romiplostim"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Percentage of Participants Who Received Rescue Medication During the Treatment Period","type":"SECONDARY","unitOfMeasure":"percentage of participants"}